{"id":18511,"date":"2021-11-18T14:03:29","date_gmt":"2021-11-18T13:03:29","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=18511"},"modified":"2021-11-18T14:04:01","modified_gmt":"2021-11-18T13:04:01","slug":"primavera-a-new-ambitious-project-to-demonstrate-how-vaccines-can-combat-antimicrobial-resistance","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/primavera-a-new-ambitious-project-to-demonstrate-how-vaccines-can-combat-antimicrobial-resistance\/","title":{"rendered":"PrIMAVeRa, a new ambitious project to demonstrate how vaccines can combat antimicrobial resistance"},"content":{"rendered":"\n

Article published on 9 November 2021 on European Vaccine Initiative website<\/a><\/p>\n\n\n\n

The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking mobilises more than \u20ac 9 million to support PrIMAVeRa, a new public-private partnership dedicated to harnessing the power of big data and AI to steer the fight against antimicrobial resistance.<\/em><\/p>\n\n\n\n

Antibiotic resistance (AMR) \u2013 the ability of microbes to evolve mechanisms that protect them from the drugs designed to kill them \u2013 is currently one of the top 10 major threats to human health[1]. <\/p>\n\n\n\n

Vaccines and monoclonal antibodies (mAb)<\/strong> \u2013 laboratory-made molecules that mimic the immune system’s ability to fight off harmful pathogens such as viruses \u2013 can play a vital role in the fight against AMR since they are not subject to the inevitable obsolescence of antimicrobials.<\/strong> Currently, there are no comprehensive data-driven tools to inform decisions about the most efficient use of vaccines and mAbs in combatting AMR. This has discouraged investment in the development of vaccines and mAbs against drug-resistant pathogens, thus increasing the burden of AMR.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n

PrIMAVeRa<\/strong> is a new European project funded by the Innovative Medicines Initiative 2 (IMI2) with the goal of developing an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding prioritisation of specific vaccines and mAbs, informing the strategic allocation of limited resources.<\/p>\n\n\n\n

\u201cThis is a highly innovative project that will highlight the important, but often forgotten role that vaccines can play in combatting AMR\u201d<\/em>, says Ole F. Olesen, Executive Director of the European Vaccine Initiative.<\/p><\/blockquote>\n\n\n\n

PriMAVeRa involves 19 partners across the EU, the UK and Russia, including 16 academic institutions and SME as well as GSK, Pfizer and Janssen as industry partners. It is coordinated by the European Vaccine Initiative (Germany), with the support of Professor Marc Bonten of the University Medical Center Utrecht (Netherlands) as scientific coordinator, and GSK as the industry lead.<\/p>\n\n\n\n

\u201cThis is the first multidisciplinary public-private partnership to combine the potentials of mathematical modelling and antibacterial vaccines to fight antimicrobial resistance\u201d<\/em>, says Professor Marc Bonten of the University Medical Center Utrecht (Netherlands), scientific coordinator of PrIMAVeRa.<\/p><\/blockquote>\n\n\n\n

\u201cWith so many pathogens and infections driving AMR there is a potentially infinite combination of vaccines and mAbs to be developed. As resources are limited, this project will hopefully provide a critical tool to decide which vaccines and monoclonals should be prioritised\u201d<\/em>, says Dr Venanzio Vella of GlaxoSmithKline Biologicals, industry leader of PrIMAVeRa.<\/p><\/blockquote>\n\n\n\n

The following main goals will be addressed by PrIMAVeRa<\/strong> in an integrated manner:<\/p>\n\n\n\n